Search Videos and More
Dana-Farber Researchers Launch New Project to Investigate How Neighborhoods Contribute to Prostate Cancer Inequity
Researchers at Dana-Farber Cancer Institute and the Rutgers University Cancer Institute are investigating what it is about neighborhoods that may increase a Black man’s risk of dying from prostate cancer.Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors
Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports.2022 GU ASCO Kidney Cancer Highlights
Kidney Cancer Highlights featuring Vincent Xu, MD and Toni Choueiri, MD2022 GU ASCO Bladder Cancer Highlights
Bladder Cancer Highlights featuring Guru Sonpavde, MD2022 GU ASCO Prostate Cancer Highlights
Prostate Cancer Highlights featuring Jacob Berchuck, MD and Chris Sweeney, MBBSASCO GU Symposium Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU SymposiumDana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.Rare Cancer: A Father's Journey with Medullary Kidney Cancer
A father and Air Force recruiter details his journey at Dana-Farber Cancer Institute with medullary kidney cancer - a rare cancer disproportionately affecting African Americans.Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.Bladder Cancer Research at ESMO
Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.Kidney Cancer Research at ESMO
Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer
T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both of these issues in patients who have undergone surgery for kidney cancer but have a high risk of recurrence.